DrugDashboards

Brompheniramine maleate, pseudoephedrine hydrochloride,

Brompheniramine maleate, pseudoephedrine hydrochloride, · BROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL · Syrup · Oral · Eywa Pharma Inc

NDC 71930-0026-43 · 473 mL in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price is down 15% over the past year, to $0.0714 per mL. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.05$0.1$0.15Dec 2020Sep 2026$0.0714
70 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$71.00
Reported to Texas DSHS · 2026 annual filing · Eywa Pharma Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$1.8M
101,044 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for brompheniramine maleate and pseudoephedrine hydrochloride (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA211170
TE code
AA
Approval date
Jun 16, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedMar 15, 2021
    Cardinal Health Inc.CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Manufacturers of Brompheniramine maleate, pseudoephedrine hydrochloride, (Syrup)

LabelerStrengthFirst seenLast seen
Eywa Pharma IncBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mLAug 26, 2026Sep 2, 2026
Eywa Pharma IncBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 10 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 30 mg/5mLJul 22, 2026Aug 19, 2026
Eywa Pharma IncBROMPHENIRAMINE MALEATE 2 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mLJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brompheniramine maleate, pseudoephedrine hydrochloride, — NDC 71930-0026-43," retrieved September 3, 2026, https://drugdashboards.com/drug/71930002643.

Free to cite with attribution — see how the data is put together.